Patient characteristics and treatment outcomes in the validation part 1.
收藏NIAID Data Ecosystem2026-05-02 收录
数据链接：
官方服务：
资源简介：
The parameters are as follows: Sex (M; Male, F; Female), Number of Pembrolizumab doses (N of Pembrolizumab doses), Progression-Free Survival in days (PFS (days)), Age, Pathology (type of cancer, in this case, Adenocarcinoma), and Red Cell Distribution Width (RDW). (XLSX)
创建时间：
2024-08-01
